Hepatocellular carcinoma is a leading cause of cancer-related death globally. The treatment of hepatocellular carcinoma is complex, with diverse therapeutic approaches and their combinations available ...
A new study in the Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic acid-inducible gene I ...
ReCerise Therapeutics Inc. ("ReCerise"), a company committed to research and development of first-in-class therapeutics in oncology, recently entered a research partnership with the National Cancer ...
Glasgow Times on MSN3d
Drug combination nearly erases liver cancer in major breakthroughA groundbreaking cancer study led by Professor Tom Bird from the Cancer Research UK Scotland Institute has discovered a drug ...
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...
Vietnam Investment Review on MSN11d
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular CarcinomaLion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
News Medical on MSN4d
Novel therapeutic approaches targeting the Wnt pathway in hepatocellular carcinomaHepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.
A new study in the peer-reviewed Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback